PMID- 22993297
OWN - NLM
STAT- MEDLINE
DCOM- 20130104
LR  - 20120920
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 32
IP  - 9
DP  - 2012 Sep
TI  - Group IIa sPLA2 inhibition attenuates NF-kappaB activity and promotes apoptosis of 
      lung cancer cells.
PG  - 3601-7
AB  - BACKGROUND/AIM: Group IIa secretory phospholipase A2 (sPLA2 IIa) has been 
      implicated in the regulation of metastasis of non-small cell lung cancer (NSCLC) 
      and the present study investigates its contribution to lung cancer growth and 
      progression. PLA2s initiate signaling in several pathways that mediate cell 
      survival including phosphatidylinositol 3-kinase-AKT (PI3K-AKT), p38 
      mitogen-activated protein kinase (p38 MAPK), extracellular-signal-regulated 
      kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells 
      (NF-kappaB). MATERIALS AND METHODS: Human NSCLC cell lines (A549 and NCI-H358) were 
      treated with a specific sPLA2 IIa inhibitor. Cells were assayed for apoptosis, 
      viability, proliferation and changes in cell morphology. Effects on AKT, p38 
      MAPK, ERK1/2 and NF-kappaB signaling pathways were investigated. RESULTS: sPLA2 IIa 
      inhibition reduced proliferation and increased apoptosis. NF-kappaB activity was 
      attenuated, whereas AKT, ERK1/2, p38 MAPK were variably affected by sPLA2 IIa 
      inhibition. NF-kappaB inhibitor-associated apoptosis confirmed the dominant role of 
      NF-kappaB. CONCLUSION: sPLA2 IIa attenuates growth and promotes apoptosis 
      predominantly via its effects on NF-kappaB activity.
FAU - Yu, Jessica A
AU  - Yu JA
AD  - Department of Surgery, University of Colorado School of Medicine, Aurora, CO 
      80045, USA.
FAU - Kalatardi, Shana
AU  - Kalatardi S
FAU - Dohse, John
AU  - Dohse J
FAU - Sadaria, Miral R
AU  - Sadaria MR
FAU - Meng, Xianzhong
AU  - Meng X
FAU - Fullerton, David A
AU  - Fullerton DA
FAU - Weyant, Michael J
AU  - Weyant MJ
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (NF-kappa B)
RN  - EC 3.1.1.4 (Phospholipases A2, Secretory)
SB  - IM
MH  - Apoptosis/*drug effects
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/enzymology/*metabolism/pathology
MH  - Cell Growth Processes/drug effects
MH  - Cell Line, Tumor
MH  - Enzyme Inhibitors/*pharmacology
MH  - Humans
MH  - Lung Neoplasms/drug therapy/enzymology/*metabolism/pathology
MH  - NF-kappa B/*metabolism
MH  - Phospholipases A2, Secretory/*antagonists & inhibitors
MH  - Phosphorylation/drug effects
EDAT- 2012/09/21 06:00
MHDA- 2013/01/05 06:00
CRDT- 2012/09/21 06:00
PHST- 2012/09/21 06:00 [entrez]
PHST- 2012/09/21 06:00 [pubmed]
PHST- 2013/01/05 06:00 [medline]
AID - 32/9/3601 [pii]
PST - ppublish
SO  - Anticancer Res. 2012 Sep;32(9):3601-7.